866-997-4948(US-Canada Toll Free)

Head And Neck Cancer - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Aug 2013

Category :

Head and Neck Cancer

No. of Pages : 208 Pages

 

Global Markets Directs, \'Head And Neck Cancer Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Head And Neck Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Head And Neck Cancer. Head And Neck Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

 

  • A snapshot of the global therapeutic scenario for Head And Neck Cancer.
  • A review of the Head And Neck Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Head And Neck Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

 

Reasons to buy

 

  • Identify and understand important and diverse types of therapeutics under development for Head And Neck Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Head And Neck Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents


Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Head And Neck Cancer Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Head And Neck Cancer 9
Head And Neck Cancer Therapeutics under Development by Companies 11
Head And Neck Cancer Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Head And Neck Cancer Therapeutics - Products under Development by Companies 20
Head And Neck Cancer Therapeutics - Products under Investigation by Universities/Institutes 23
Companies Involved in Head And Neck Cancer Therapeutics Development 24
Bristol-Myers Squibb Company 24
Boehringer Ingelheim GmbH 25
Eli Lilly and Company 26
Inovio Biomedical Corporation 27
Gilead Sciences, Inc. 28
GenVec, Inc. 29
Piramal Healthcare Limited 30
Bio-Path Holdings, Inc. 31
Millennium Pharmaceuticals, Inc. 32
Novartis AG 33
Daewoong Pharmaceutical Co., Ltd. 34
Taiho Pharmaceutical Co., Ltd. 35
Takara Holdings Inc. 36
Cell Therapeutics, Inc. 37
CEL-SCI Corporation 38
Advaxis, Inc. 39
Bionomics Limited 40
Northwest Biotherapeutics, Inc. 41
Oncolytics Biotech Inc. 42
Curis, Inc. 43
Transgene SA 44
Panacea Biotec Limited 45
Natco Pharma Limited 46
Nanobiotix 47
Wilex AG 48
Multimmune GmbH 49
Hawthorn Pharmaceuticals, Inc. 50
PDS Biotechnology Corporation 51
Oncolys BioPharma Inc. 52
Etubics Corporation 53
InteRNA Technologies B.V. 54
Genelux Corporation 55
IRX Therapeutics, Inc. 56
Pique Therapeutics 57
ISU ABXIS Co.,Ltd. 58
Jiangsu Kanion Pharmaceutical Co., Ltd. 59
Incuron 60
Head And Neck Cancer - Therapeutics Assessment 61
Assessment by Monotherapy Products 61
Assessment by Combination Products 62
Assessment by Route of Administration 63
Assessment by Molecule Type 65
Drug Profiles 67
alisertib - Drug Profile 67
paclitaxel poliglumex - Drug Profile 70
CUDC-101 - Drug Profile 74
panobinostat - Drug Profile 76
ENKASTIM-ev - Drug Profile 81
PDS-0101 - Drug Profile 82
DWP-418 - Drug Profile 84
Leukocyte Interleukin Injection - Drug Profile 85
OBP-301 - Drug Profile 87
pemetrexed disodium - Drug Profile 88
CBL-0137 - Drug Profile 94
pelareorep - Drug Profile 95
TG-4023 - Drug Profile 99
GM-CT-01 - Drug Profile 101
P-276 - Drug Profile 104
BP-100-1.02 - Drug Profile 106
IRX-2 - Drug Profile 107
HF-10 - Drug Profile 109
BNC-105 - Drug Profile 110
Mixed Bacterial Vaccine - Drug Profile 112
GL-ONC-1 - Drug Profile 113
afatinib - Drug Profile 115
Cyclin B1 Targeted Vaccine - Drug Profile 117
nelfinavir mesylate - Drug Profile 118
nimotuzumab - Drug Profile 119
DCVax-Head & Neck - Drug Profile 122
Haw mAb-12 - Drug Profile 123
PT-207 - Drug Profile 124
Probodies Program - Drug Profile 125
(tegafur + gimeracil + oteracil potassium) - Drug Profile 126
HPV-Head and Neck Cancer Vaccine - Drug Profile 129
WX-UK1 - Drug Profile 130
Squamous Antibodies - Drug Profile 132
ONS-1015 - Drug Profile 133
EC-70124 - Drug Profile 135
ISU-101 - Drug Profile 136
ganciclovir with ADV-TK - Drug Profile 137
SynCon HPV Vaccine - Drug Profile 138
Revercom - Drug Profile 139
BXQ-350 - Drug Profile 140
NT-113 - Drug Profile 142
miRNA Targeting p53 - Drug Profile 143
MCT-1 Inhibitors - Drug Profile 144
EDC-2 - Drug Profile 146
Recombinant Delivery Proteins Derived From Interleukin-13 - Drug Profile 147
cetuximab biosimilar - Drug Profile 148
MN-4 - Drug Profile 149
Pactamycin Analogs - Drug Profile 150
AGM-120 - Drug Profile 151
cetuximab Biosimilar - Drug Profile 152
Ad5 E-10A - Drug Profile 153
Anti-EGFR Antibody - Drug Profile 154
RNA Aptamer - Drug Profile 155
cetuximab biosimilar - Drug Profile 156
Head And Neck Cancer Therapeutics - Drug Profile Updates 157
Head And Neck Cancer Therapeutics - Discontinued Products 191
Head And Neck Cancer Therapeutics - Dormant Products 192
Non-Hodgkin Lymphoma - Product Development Milestones 194
Featured News & Press Releases 194


Appendix 203
Methodology 203
Coverage 203
Secondary Research 203
Primary Research 203
Expert Panel Validation 203
Contact Us 204
Disclaimer 204

List of Table


Number of Products Under Development for Head And Neck Cancer, H2 2013 13
Products under Development for Head And Neck Cancer - Comparative Analysis, H2 2013 14
Number of Products under Development by Companies, H2 2013 16
Number of Products under Development by Companies, H2 2013 (Contd..1) 17
Number of Products under Development by Companies, H2 2013 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H2 2013 19
Comparative Analysis by Late Stage Development, H2 2013 20
Comparative Analysis by Mid Clinical Stage Development, H2 2013 21
Comparative Analysis by Early Clinical Stage Development, H2 2013 22
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 23
Products under Development by Companies, H2 2013 24
Products under Development by Companies, H2 2013 (Contd..1) 25
Products under Development by Companies, H2 2013 (Contd..2) 26
Products under Investigation by Universities/Institutes, H2 2013 27
Bristol-Myers Squibb Company, H2 2013 28
Boehringer Ingelheim GmbH, H2 2013 29
Eli Lilly and Company, H2 2013 30
Inovio Biomedical Corporation, H2 2013 31
Gilead Sciences, Inc., H2 2013 32
GenVec, Inc., H2 2013 33
Piramal Healthcare Limited, H2 2013 34
Bio-Path Holdings, Inc., H2 2013 35
Millennium Pharmaceuticals, Inc., H2 2013 36
Novartis AG, H2 2013 37
Daewoong Pharmaceutical Co., Ltd., H2 2013 38
Taiho Pharmaceutical Co., Ltd., H2 2013 39
Takara Holdings Inc., H2 2013 40
Cell Therapeutics, Inc., H2 2013 41
CEL-SCI Corporation, H2 2013 42
Advaxis, Inc., H2 2013 43
Bionomics Limited, H2 2013 44
Northwest Biotherapeutics, Inc., H2 2013 45
Oncolytics Biotech Inc., H2 2013 46
Curis, Inc., H2 2013 47
Transgene SA, H2 2013 48
Panacea Biotec Limited, H2 2013 49
Natco Pharma Limited, H2 2013 50
Nanobiotix, H2 2013 51
Wilex AG, H2 2013 52
Multimmune GmbH, H2 2013 53
Hawthorn Pharmaceuticals, Inc., H2 2013 54
PDS Biotechnology Corporation, H2 2013 55
Oncolys BioPharma Inc., H2 2013 56
Etubics Corporation, H2 2013 57
InteRNA Technologies B.V., H2 2013 58
Genelux Corporation, H2 2013 59
IRX Therapeutics, Inc., H2 2013 60
Pique Therapeutics, H2 2013 61
ISU ABXIS Co.,Ltd., H2 2013 62
Jiangsu Kanion Pharmaceutical Co., Ltd., H2 2013 63
Incuron, H2 2013 64
Assessment by Monotherapy Products, H2 2013 65
Assessment by Combination Products, H2 2013 66
Assessment by Stage and Route of Administration, H2 2013 68
Assessment by Stage and Molecule Type, H2 2013 70
Head And Neck Cancer Therapeutics - Drug Profile Updates 161
Head And Neck Cancer Therapeutics - Discontinued Products 195
Head And Neck Cancer Therapeutics - Dormant Products 196
Head And Neck Cancer Therapeutics - Dormant Products (Contd..1) 197

List of Chart


Number of Products under Development for Head And Neck Cancer, H2 2013 13
Products under Development for Head And Neck Cancer - Comparative Analysis, H2 2013 14
Products under Development by Companies, H2 2013 15
Products under Investigation by Universities/Institutes, H2 2013 19
Late Stage Products, H2 2013 20
Mid Clinical Stage Products, H2 2013 21
Early Clinical Stage Products, H2 2013 22
Discovery and Pre-Clinical Stage Products, H2 2013 23
Assessment by Monotherapy Products, H2 2013 65
Assessment by Combination Products, H2 2013 66
Assessment by Route of Administration, H2 2013 67
Assessment by Stage and Route of Administration, H2 2013 68
Assessment by Molecule Type, H2 2013 69
Assessment by Stage and Molecule Type, H2 2013 70

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *